| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/TP.0B013E3181CEE42F |
| P698 | PubMed publication ID | 20224515 |
| P50 | author | David R. Snydman | Q47739390 |
| Camille Nelson Kotton | Q56379985 | ||
| P2093 | author name string | Angela M Caliendo | |
| Anders Asberg | |||
| Deepali Kumar | |||
| Atul Humar | |||
| Sunwen Chou | |||
| Upton Allen | |||
| Transplantation Society International CMV Consensus Group | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Cytomegalovirus | Q6946 |
| organ transplantation | Q69253852 | ||
| P304 | page(s) | 779-795 | |
| P577 | publication date | 2010-04-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | International consensus guidelines on the management of cytomegalovirus in solid organ transplantation | |
| P478 | volume | 89 |
| Q42489108 | "Immuknow" to measurement of cell-mediated immunity in renal transplant recipients undergoing short-term evaluation |
| Q45358050 | (Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation |
| Q40572871 | 1,25 Dihydroxyvitamin D circulating levels, calcitriol administration, and incidence of acute rejection, CMV infection, and polyoma virus infection in renal transplant recipients |
| Q42717415 | 17-allylamino-17-(demethoxy)geldanamycin (17-AAG) is a potent and effective inhibitor of human cytomegalovirus replication in primary fibroblast cells |
| Q36929597 | 24 Weeks of Valganciclovir Prophylaxis in Children After Renal Transplantation: A 4-Year Experience |
| Q37855078 | A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients |
| Q58842025 | A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiologya |
| Q90068199 | A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection |
| Q37036994 | A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)(a). |
| Q38938297 | A risk-stratified approach to cytomegalovirus prevention in pediatric solid organ transplant recipients |
| Q54290180 | A stringent preemptive protocol reduces cytomegalovirus disease in the first 6 months after kidney transplantation. |
| Q37057099 | Acute Cytomegalovirus Hepatitis in an Immunocompetent Host as a Reason for Upper Right Abdominal Pain |
| Q35282503 | Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation |
| Q37965695 | Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy |
| Q47397747 | An Early Immediate Early Protein IE-1-Specific T-Cell Polyfunctionality Is Associated With a Better Control of Cytomegalovirus Reactivation in Kidney Transplantation |
| Q34448341 | An analysis of regulatory T-cell and Th-17 cell dynamics during cytomegalovirus replication in solid organ transplant recipients |
| Q35623271 | An experience of liver transplantation in Latin America: a medical center in Colombia. |
| Q42577232 | An international multicenter performance analysis of cytomegalovirus load tests |
| Q30430427 | Antiviral Drug Resistance of Human Cytomegalovirus |
| Q38370342 | Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients |
| Q24635330 | Antiviral drugs for viruses other than human immunodeficiency virus |
| Q24200697 | Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients |
| Q83828856 | Antiviral prophylaxis versus preemptive therapy to prevent cytomegalovirus infection and related death in liver transplantation: a retrospective study with propensity score matching |
| Q43992958 | Antiviral treatment of cytomegalovirus infection: an update |
| Q52647635 | Applications of gold nanoparticles in virus detection. |
| Q42284503 | Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study |
| Q90418026 | Association between lymphocyte subsets and cytomegalovirus infection status among patients with systemic lupus erythematosus: A pilot study |
| Q37895908 | Biomarkers of over-immunosuppression. |
| Q26824869 | CMV: Prevention, Diagnosis and Therapy |
| Q38179174 | Cellular immune therapy for viral infections in transplant patients |
| Q34674064 | Characterization of cytomegalovirus disease in solid organ transplant recipients by markers of inflammation in plasma |
| Q41041259 | Clinical Utility of Viral Load in the Management of Cytomegalovirus Infection in Solid Organ Transplant Patients in Kuwait |
| Q38067694 | Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients |
| Q38271850 | Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection. |
| Q40272828 | Co-infection and clinical impact of human herpesvirus 5 and 6 in liver transplantation |
| Q64099934 | Colon perforation due to antigenemia-negative cytomegalovirus gastroenteritis after liver transplantation: A case report and review of literature |
| Q42249125 | Combination of immunoglobulins and natural killer cells in the context of CMV and EBV infection |
| Q37867765 | Common infections in the lung transplant recipient |
| Q60924062 | Common viral infections in kidney transplant recipients |
| Q41606013 | Comparative evaluation of the QIAsymphony RGQ system with the easyMAG/R-gene combination for the quantitation of cytomegalovirus DNA load in whole blood |
| Q38875533 | Comparison of automated nucleic acid extraction methods for the detection of cytomegalovirus DNA in fluids and tissues |
| Q37036219 | Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients |
| Q42270373 | Comparison of two quantitative real-time CMV-PCR tests calibrated against the 1st WHO international standard for viral load monitoring of renal transplant patients |
| Q40955529 | Complexity of Host Micro-RNA Response to Cytomegalovirus Reactivation After Organ Transplantation |
| Q28950688 | Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy |
| Q36288594 | Correlation and clinical utility of pp65 antigenemia and quantitative polymerase chain reaction assays for detection of cytomegalovirus in pediatric renal transplant patients |
| Q27023452 | Current and potential treatments for ubiquitous but neglected herpesvirus infections |
| Q34390310 | Current concepts on cytomegalovirus infection after liver transplantation |
| Q42850271 | Cytomegalovirus DNA quantification using an automated platform for nucleic acid extraction and real-time PCR assay setup |
| Q54299167 | Cytomegalovirus Disease of the Upper Gastrointestinal Tract: A 10-Year Retrospective Study. |
| Q47180545 | Cytomegalovirus Infection after Renal Transplantation: Occurrence, Clinical Features, and the Cutoff for Antigenemia in a University Hospital in Brazil. |
| Q38689823 | Cytomegalovirus Infection in Pediatric Solid Organ Transplant Recipients: a Focus on Prevention |
| Q59263071 | Cytomegalovirus Replication Within the Lung Allograft Is Associated With Bronchiolitis Obliterans Syndrome |
| Q42554715 | Cytomegalovirus Treatment |
| Q34483416 | Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility |
| Q39155340 | Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance |
| Q91750064 | Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal Valganciclovir Prophylaxis |
| Q53651832 | Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis. |
| Q36614140 | Cytomegalovirus disease in African-American kidney transplant patients |
| Q42283057 | Cytomegalovirus disease in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis. |
| Q42254755 | Cytomegalovirus disease in patients with common variable immunodeficiency: three case reports |
| Q34786700 | Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial |
| Q38310894 | Cytomegalovirus in pediatric systemic lupus erythematosus: prevalence and clinical manifestations |
| Q38044829 | Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment |
| Q42216126 | Cytomegalovirus infection after acute rejection therapy in seropositive kidney transplant recipients |
| Q83396353 | Cytomegalovirus infection after prophylactic valganciclovir therapy post-kidney transplantation: case reports |
| Q37577044 | Cytomegalovirus infection in childhood-onset systemic lupus erythematosus |
| Q38242802 | Cytomegalovirus infection in liver transplant recipients: updates on clinical management |
| Q40068430 | Cytomegalovirus infection in patients with lupus nephritis: clinical and laboratory features and therapeutic considerations |
| Q42250541 | Cytomegalovirus infection in renal transplant recipients: one center's experience |
| Q37098580 | Cytomegalovirus infection in renal transplantation: clinical aspects, management and the perspectives. |
| Q84028370 | Cytomegalovirus infection in solid organ transplantation |
| Q52728252 | Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study. |
| Q37359332 | Cytomegalovirus infections in solid organ transplantation: a review |
| Q42281180 | Cytomegalovirus prophylaxis in pediatric kidney transplantation: the Dutch experience. |
| Q36434411 | Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy |
| Q37825594 | Cytomegalovirus risk, prevention, and management in pediatric solid organ transplantation |
| Q37778827 | Cytomegalovirus-associated renal allograft rejection: new challenges for antiviral preventive strategies |
| Q92464936 | Cytomegalovirus-induced vasculopathy and anogenital skin ulcers in a patient with multiple myeloma |
| Q60614891 | Cytomegalovirus-specific T cells are detectable in early childhood and allow assignment of the infection status in children with passive maternal antibodies |
| Q35895910 | Cytomegalovirus: recent progress in understanding pathogenesis and control |
| Q37272283 | Detection of cytomegalovirus DNA in plasma as an adjunct diagnostic for gastrointestinal tract disease in kidney and liver transplant recipients |
| Q34975934 | Detection of cytomegalovirus drug resistance mutations by next-generation sequencing |
| Q38205920 | Diarrhea caused by viruses in transplant recipients |
| Q38818062 | Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene |
| Q36334306 | Differentiation-Coupled Induction of Human Cytomegalovirus Replication by Union of the Major Enhancer Retinoic Acid, Cyclic AMP, and NF-κB Response Elements |
| Q42249961 | Does the calcineurin inhibitor have influence on cytomegalovirus infection in heart transplantation? |
| Q42852632 | Drug-resistant cytomegalovirus in transplant recipients: a French cohort study |
| Q52564748 | Earlier and higher rates of cytomegalovirus infection in pediatric liver transplant recipients as compared to adults: An observational study. |
| Q37026107 | Early Enteral Feeding After Living Donor Liver Transplantation Prevents Infectious Complications: A Prospective Pilot Study |
| Q44622526 | Early onset adenovirus infection after simultaneous kidney-pancreas transplant |
| Q39118387 | Effect of Cytomegalovirus Infection on Survival of Older Kidney Transplant Patients (D+/R+): Impact of Valganciclovir Prophylaxis Versus Preemptive Therapy. |
| Q38061056 | Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms |
| Q36321541 | Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients |
| Q38364698 | Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis |
| Q34342514 | Emerging rapid resistance testing methods for clinical microbiology laboratories and their potential impact on patient management |
| Q58854031 | Esquemas de prevención de la infección por citomegalovirus: terapia anticipada frente a profilaxis universal |
| Q35866312 | Evaluation of the IMMULITE® 2000 CMV IgM assay |
| Q95353303 | Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, He |
| Q42258701 | Evaluation of virus-specific cellular immune response in transplant patients. |
| Q43523397 | Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation. |
| Q39659062 | First face composite-tissue transplant recipient successfully treated for cytomegalovirus infection with preemptive valganciclovir treatment |
| Q27026499 | Flow cytometry and solid organ transplantation: a perfect match |
| Q28680756 | Fully automated quantification of cytomegalovirus (CMV) in whole blood with the new sensitive Abbott RealTime CMV assay in the era of the CMV international standard |
| Q42816813 | Ganciclovir Pharmacokinetic Parameters Do Not Change When Extending Valganciclovir Cytomegalovirus Prophylaxis From 100 to 200 Days |
| Q84859127 | Ganciclovir transiently attenuates murine cytomegalovirus-associated renal allograft inflammation |
| Q38415861 | Ganciclovir-Resistant Cytomegalovirus Infection in a Kidney Transplant Recipient Successfully Treated with Foscarnet and Everolimus |
| Q35227636 | Ganciclovir-resistant cytomegalovirus infection in renal transplantation |
| Q44264370 | Ganciclovir-resistant cytomegalovirus infection in transplanted patients: utility of drug monitoring. |
| Q49951116 | Heart Transplantation and Risk of Cardiac Vasculopathy Development: What Factors Are Important? |
| Q50177607 | High-dose Valganciclovir Treatment for Resistant Cytomegalovirus Colitis due to UL97 and UL54 Mutations |
| Q35791488 | Hospital Admission following Acute Kidney Injury in Kidney Transplant Recipients Is Associated with a Negative Impact on Graft Function after 1-Year |
| Q26850340 | Human CMV-specific T-cell responses in kidney transplantation; toward changing current risk-stratification paradigm |
| Q37726821 | Human cytomegalovirus detection by real-time PCR and pp65-antigen test in hematopoietic stem cell transplant recipients: a challenge in low and middle-income countries |
| Q44603535 | Human cytomegalovirus infection in humanized liver chimeric mice |
| Q37888397 | Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment. |
| Q39476453 | Human herpesvirus vaccines and future directions. |
| Q47552304 | Immune monitoring of infectious complications in transplant patients: An important step towards improved clinical management |
| Q26992146 | Immune regulation of human herpesviruses and its implications for human transplantation |
| Q37866813 | Immunological risk factors for infection after immunosuppressive and biologic therapies. |
| Q40267366 | Impact of Everolimus and Low-Dose Cyclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation. |
| Q47430164 | Impact of HLA-G 14-bp polymorphism on acute rejection and cytomegalovirus infection in kidney transplant recipients from northwestern China |
| Q42202589 | Impact of Pharmacist Involvement in Early Identification and Enrollment in Patient Assistance Programs on CMV Outcomes in Transplantation |
| Q42252471 | Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients |
| Q41947385 | Importance of the cytomegalovirus seropositive recipient as a contributor to disease burden after solid organ transplantation |
| Q41233197 | In vitro evaluation of cytomegalovirus-specific hyperimmune globulins vs. standard intravenous immunoglobulins |
| Q35946563 | Incidence, Risk Factors and Outcomes of Delayed-onset Cytomegalovirus Disease in a Large Retrospective Cohort of Lung Transplant Recipients |
| Q34729119 | Incidence, risk factors, and outcomes of delayed-onset cytomegalovirus disease in a large, retrospective cohort of heart transplant recipients |
| Q36977623 | Induction of innate immune signatures following polyepitope protein-glycoprotein B-TLR4&9 agonist immunization generates multifunctional CMV-specific cellular and humoral immunity |
| Q30238810 | Infection in Organ Transplantation |
| Q27023182 | Infections after orthotopic liver transplantation |
| Q34993661 | Infections in liver transplant recipients. |
| Q41744581 | Interferon-gamma gene polymorphism +874 A/T is associated with an increased risk of cytomegalovirus infection among Hispanic renal transplant recipients |
| Q40158843 | Interlaboratory quality control of total HIV-1 DNA load measurement for multicenter reservoir studies |
| Q35977398 | Interpreting quantitative cytomegalovirus DNA testing: understanding the laboratory perspective |
| Q38475761 | Is cytomegalovirus infection dangerous in cytomegalovirus-seropositive recipients after liver transplantation? |
| Q36288302 | Isolated unilateral cytomegalovirus retinitis: a rare long-term complication after pediatric liver transplantation. |
| Q42102339 | JAID/JSC Guidelines for the Treatment of Respiratory Infectious Diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy - The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committ |
| Q42223053 | Kinetics of peripheral blood lymphocyte subpopulations predicts the occurrence of opportunistic infection after kidney transplantation |
| Q38168278 | Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature |
| Q37957446 | Leflunomide for cytomegalovirus: bench to bedside |
| Q39325580 | Letermovir Treatment of Human Cytomegalovirus Infection Antiinfective Agent |
| Q38149379 | Life-threatening infection in transplant recipients |
| Q34646976 | Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation |
| Q36200933 | Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation |
| Q42242133 | Low-dose valganciclovir for cytomegalovirus prophylaxis in heart transplant recipients |
| Q56505206 | Lung Transplantation |
| Q38010486 | Lung transplant infection |
| Q86857643 | Lung transplantation |
| Q38822159 | Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. |
| Q37803335 | Management of cytomegalovirus infection in solid organ transplantation |
| Q38003050 | Management of polyomavirus-associated nephropathy in renal transplant recipients |
| Q37892559 | Management of viral infections in solid organ transplant recipients |
| Q36922932 | Minimizing infection risks after paediatric organ transplants: Advice for practitioners |
| Q37848137 | Monitoring and managing viral infections in pediatric renal transplant recipients |
| Q40112338 | Mucormycosis and Cytomegalovirus Co-infection in Renal Transplant Recipients |
| Q89366245 | New Developments in the Management of Cytomegalovirus Infection After Transplantation |
| Q37358692 | Pancreatic anastomosis leak 15 years after simultaneous pancreas-kidney transplantation from late-onset allograft cytomegalovirus duodenal ulcers presenting with gross hematuria |
| Q89037537 | Pediatric lung transplantation |
| Q42039829 | Peripheral blood leukocytes and serum nested polymerase chain reaction are complementary methods for monitoring active cytomegalovirus infection in transplant patients |
| Q90705191 | Persistent Primary Cytomegalovirus Infection After Deceased Donor Kidney Transplant: Ganciclovir Susceptibility of Human Cytomegalovirus With UL97 D605E Mutation: A Case Report |
| Q47766934 | Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients |
| Q36759073 | Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage. |
| Q34687313 | Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy |
| Q34605186 | Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis |
| Q40290973 | Post-renal transplant cytomegalovirus infection: study of risk factors |
| Q37706330 | Practical guidelines: lung transplantation in patients with cystic fibrosis |
| Q46777568 | Pre-emptive therapy for the cytomegalovirus infection after liver transplantation in endemic areas and its optimal diagnostic method. |
| Q53120860 | Preemptive therapy versus valgancyclovir prophylaxis in cytomegalovirus-positive kidney transplant recipients receiving antithymocyte globulin induction. |
| Q42259440 | Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. |
| Q45391655 | Pretransplant interferon-γ secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation. |
| Q27005922 | Prevention of Transfusion-Transmitted Cytomegalovirus Infections: Which is the Optimal Strategy? |
| Q38124439 | Prevention of cytomegalovirus following solid organ transplantation: a literature review |
| Q33932079 | Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients |
| Q36216553 | Priorities for CMV vaccine development |
| Q40956620 | Prophylactic CMV therapy does not improve three-yr patient and graft survival compared to preemptive therapy. |
| Q33392425 | Prophylactic Therapy With Valganciclovir in High-Risk (Cytomegalovirus D+/R−) Kidney Transplant Recipients: A Single-Center Experience |
| Q44100013 | Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients |
| Q44463291 | Prophylaxis, preemption and drug resistance in CMV infection: too little, too much or just right? |
| Q43909393 | Prospective analysis of human cytomegalovirus DNAemia and specific CD8+ T cell responses in lung transplant recipients. |
| Q88196240 | Protracted severe systemic cytomegalovirus disease in an immunosuppressed patient with ulcerative colitis |
| Q38025800 | Pulmonary infections following lung transplantation |
| Q58074723 | QuantiFERON®-CMV assay for the assessment of cytomegalovirus cell-mediated immunity |
| Q36147994 | Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive Therapy. |
| Q36265398 | Reactivated cytomegalovirus proctitis in an immunocompetent patient presenting as nosocomial diarrhea: a case report and literature review |
| Q34349745 | Recent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases |
| Q42844201 | Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis |
| Q41218897 | Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses. |
| Q52845695 | Renal Association Clinical Practice Guideline on post-operative care of the kidney transplant recipient. |
| Q42352189 | Repeated CMV infection in a heart transplantation patient. |
| Q40745646 | Resolution of Mild Ganciclovir-Resistant Cytomegalovirus Disease with Reduced-Dose Cidofovir and CMV-Hyperimmune Globulin |
| Q35785403 | Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir. |
| Q41892541 | Risk factors for cytomegalovirus disease in seropositive renal transplant recipients; a single-center case-controlled study |
| Q38286630 | Risk factors of cytomegalovirus infection after pediatric liver transplantation |
| Q40293836 | Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study. |
| Q38034186 | Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis |
| Q36505193 | Role of defective thymic function in onset of ganciclovir-resistant cytomegalovirus after cord blood transplantation |
| Q38055888 | Role of molecular diagnostics in the management of infectious disease emergencies. |
| Q46499070 | Réduire les risques d’infection au minimum après une transplantation d’organe en pédiatrie : des conseils aux praticiens |
| Q57568998 | Simultaneous Monitoring of Cytomegalovirus-Specific Antibody and T-cell levels in Seropositive Heart Transplant Recipients |
| Q42787459 | Simultaneous monitoring of CMV and human herpesvirus 6 infections and diseases in liver transplant patients: one-year follow-up |
| Q33362824 | Special considerations for the use of lung transplantation in pediatrics. |
| Q27014778 | State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician |
| Q37773992 | Strategies for managing cytomegalovirus in transplant recipients |
| Q38285782 | Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients. |
| Q86519756 | Successful ganciclovir treatment of primary cytomegalovirus infection containing the UL97 mutation N510S in an intestinal graft recipient |
| Q36066896 | Systematic Evaluation of Different Nucleic Acid Amplification Assays for Cytomegalovirus Detection: Feasibility of Blood Donor Screening. |
| Q93052080 | The Interferon-Gamma +874 A/T Polymorphism Is Not Associated With CMV Infection After Kidney Transplantation |
| Q92128110 | The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19 |
| Q43601622 | The association between cytomegalovirus immune globulin and long-term recipient and graft survival following liver transplantation |
| Q35684511 | The biology of cytomegalovirus drug resistance |
| Q90101444 | The detection of the cytomegalovirus DNA in the colonic mucosa of patients with ulcerative colitis is associated with increased long-term risk of proctocolectomy: results from an outpatient IBD clinic |
| Q40173113 | The effect of different immunoprophylaxis regimens on post-transplant cytomegalovirus (CMV) infection in CMV-seropositive liver transplant recipients |
| Q44253291 | The effects of preemptive therapy using a very low threshold of pp65 antigenemia to prevent cytomegalovirus disease in kidney transplant recipients: a single-center experience |
| Q51818445 | The impact of donor cytomegalovirus DNA on transfusion strategies for at-risk patients. |
| Q50497242 | The menace of CMV disease after small bowel transplantation: bearer of bad news! |
| Q38631773 | The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase |
| Q37791408 | The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation |
| Q87425046 | The role of therapeutic drug monitoring in the treatment of cytomegalovirus disease in kidney transplantation |
| Q42205282 | Therapeutic approach to respiratory infections in lung transplantation |
| Q42203312 | Timing of CMV-specific effector memory T cells predicts viral replication and survival after allogeneic hematopoietic stem cell transplantation |
| Q38667640 | Transfusion-transmitted CMV infection - current knowledge and future perspectives. |
| Q42229229 | Transient residence of a seropositive organ is sufficient to transfer human cytomegalovirus to a seronegative recipient. |
| Q36244128 | Transplant Infectious Diseases: A Review of the Scientific Registry of Transplant Recipients Published Data |
| Q38875887 | Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update |
| Q45019901 | Treatment of cytomegalovirus disease |
| Q38176940 | Treatment of cytomegalovirus infections beyond acute disease to improve human health |
| Q36724385 | Two strategies for prevention of cytomegalovirus infections after liver transplantation |
| Q42229846 | Universal valganciclovir prophylaxis significantly reduces episodes of first-year cytomegalovirus disease and biopsy-proven acute rejection in kidney transplant recipients. |
| Q37863894 | Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation |
| Q37962447 | Update on cytomegalovirus infections of the gastrointestinal system in solid organ transplant recipients |
| Q35452656 | Vaccination in solid-organ transplantation candidates: time for a benefit/risk assessment |
| Q37949634 | Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation |
| Q38087371 | Valganciclovir: therapeutic role in pediatric solid organ transplant recipients |
| Q36490685 | Validation of cytomegalovirus immune competence assays for the characterization of CD8(+) T cell responses posttransplant |
| Q38064527 | Viral infections and their management in patients with chronic lymphocytic leukemia. |
| Q54354990 | Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation. |
| Q42274589 | Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the World Health Organization international standard is predictive of CMV disease resolution in transplant recipients |
| Q84028031 | [Key definitions and concepts in cytomegalovirus: infection versus disease. Replication, viral load, universal prophylaxis. Preemptive therapy] |
| Q54310899 | [Lights and shadows of cytomegalovirus infection in solid organ transplantation]. |
| Q87193472 | [Lung transplantation] |
| Q84028073 | [Prophylaxis of cytomegalovirus infection in intestinal transplantation] |
| Q54310892 | [Prophylaxis of cytomegalovirus infection in pancreatic transplantation]. |
Search more.